IACP To FDA: Allow Compounding To Provide Lower-Cost Versions Of Drugs

An international group of compounders told FDA it should revise its policies to allow compounding as a tool to provide patients access to lower-cost versions of high-cost drugs that they otherwise might not be able to afford. However, advocacy group Public Citizen told Inside Health Policy that a lower price is not enough to justify compounding of commercially available drugs, noting compounded products don't face the same regulations as FDA-approved drugs and thus could pose more risk to patients.

source